Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiences.
Recurrence of disease after autologous hematopoietic stem cell transplantation is at least partly due to contamination of the reinfused transplant with tumor cells, thereby limiting the clinical outcome after transplantation. On the other hand, immunological effector cells are capable of purging bone marrow transplants in vitro and of destroying disseminated tumor cells in vivo. Cellular immunotherapy subsequent to autologous stem cell transplantation is therefore expected to have a major impact on recurrence rates of the disease. In this review, we present various strategies utilizing immunologic effector cells for elimination of disseminated tumor cells and discuss the advantages and limitations of cellular immunotherapy after autologous hematopoietic stem cell transplantation.
Abken
Hinrich
H
Klinik I für Innere Medizin, Labor Tumorgenetik, Universität zu Köln, Köln, Germany.
Hombach
Andreas
A
Reinhard
Günter
G
Märten
Angela
A
Schlimper
Claudia
C
Glasmacher
Axel
A
Bieber
Thomas
T
Schmidt-Wolf
Ingo G H
IG
D017252:CD3 Complex / Q000096:biosynthesis; D019002:CD56 Antigen / Q000096:biosynthesis; D003131:Combined Modality Therapy / Q000379:methods*; D003713:Dendritic Cells / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000378:metabolism; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*
D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2